Abstract:KEYWORDS: The desire to further improve children's healthcare triggered a U.S. law in 1997 that rewarded companies for pediatric drug studies, a movement called in its entirety 'Pediatric Drug Development' (PDD) [ Citation 1 ]. In 2001, the FDA predicted measurable improvements [ Citation 2 ]. A European Union (EU) law followed [ Citation 3 ], also called 'Better Medicines for Children' (BMfC) by the European Commission [ Citation 4 ]. Preparing a pro&con discussion in 2007, we could not find an academic to play the devil's advocate, so strong was enthusiasm about PDD/BMfC.

Pediatric pharmacotherapy: a challenge with complex roots